Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
eMch61B42sg7T0xC
